ARKG vs ARKW Stock Comparison: AI Score, Valuation, Performance and Upside
ARKG and ARKW sit in related but distinct corners of the ETF landscape — ARKG centers on concentrated, actively managed exposure to genomic and biotech innovation, while ARKW focuses on concentrated, actively managed exposure to next-gen internet and AI disruption themes. Investors choosing between them should weigh how each fund's strategy lines up with their own goals rather than assuming they're interchangeable.
Choosing between ARKG and ARKW comes down to which specific exposure — concentrated, actively managed exposure to genomic and biotech innovation or concentrated, actively managed exposure to next-gen internet and AI disruption themes — better matches the role you want this holding to play in a diversified portfolio.
ARKG holds the edge across 4 of 5 key metrics in this comparison. ARKG has delivered stronger 1-year price return (+68.44% vs -10.34% for ARKW).
- want concentrated, actively managed exposure to genomic and biotech innovation
- prefer ARK Invest's approach and fund lineup
- value pure-play, high-conviction exposure to gene-editing and genomics innovation
- are comfortable with extremely volatile with a history of deep, multi-year drawdowns
- want concentrated, actively managed exposure to next-gen internet and AI disruption themes
- prefer ARK Invest's approach and fund lineup
- value high-conviction, actively managed exposure to disruptive internet trends
- are comfortable with extremely volatile with deep historical drawdowns
| Metric | ARKG | ARKW |
|---|---|---|
| ETF scorei | 28.1 | 28.8 |
| Latest closei | $49.69 | $147.00 |
| 1M returni | -12.47% | -11.39% |
| 3M returni | +20.49% | +1.17% |
| 6M returni | +59.98% | +0.73% |
| 1Y returni | +68.44% | -10.34% |
The ETF score weights long-term returns and risk-adjusted performance most heavily, but still rewards low expense ratios, larger fund size, and broader diversification — so it can favor low-cost, broad, mega-cap funds over smaller thematic or actively-managed funds even when the latter have delivered stronger returns.
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ARKG | ARKW |
|---|---|---|
| 1Y ago | $16.84K (+68.4%) started 2025-11-04 | $9.1K (-9.0%) started 2025-11-04 |
| 5Y ago | $6.46K (-35.4%) started 2021-11-05 | $10.16K (+1.6%) started 2021-11-05 |
| 10Y ago | $34.49K (+244.9%) started 2016-11-07 | $89.68K (+796.8%) started 2016-11-07 |
Hypothetical — past performance does not guarantee future results.
| Metric | ARKG | ARKW |
|---|---|---|
| Expense ratioi | 0.75% | 0.76% |
| Total assets (AUM)i | $2.21B | $1.68B |
| Dividend yieldi | 0.00% | 1.60% |
| Trailing P/Ei | N/A | 32.76 |
| Betai | 1.77 | 2.06 |
| 52-week change | 68.44% | -10.34% |
| Metric | ARKG | ARKW |
|---|---|---|
| 1Y returni | +68.44% | -10.34% |
| 6M returni | +59.98% | +0.73% |
| 3M returni | +20.49% | +1.17% |
| 1M returni | -12.47% | -11.39% |
| 1Y Sharpe ratio | 1.27 | -0.29 |
| Betai | 1.77 | 2.06 |
| Dividend yieldi | 0.00% | 1.60% |
| 5Y CAGR | -8.50% | -0.55% |
Over the past year, ARKG and ARKW have moved moderately in the same direction (correlation of 0.61), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | ARKG | ARKW |
|---|---|---|---|
| 1Y | Growthi | +68.44% | -10.34% |
| CAGRi | +68.50% | -10.35% | |
| Volatilityi | 45.78% | 33.46% | |
| Sharpe ratioi | 1.27 | -0.29 | |
| Sortino ratioi | 1.99 | -0.40 | |
| Max drawdowni | 27.51% | 31.15% | |
| Current drawdowni | 12.47% | 12.15% | |
| Avg drawdowni | 8.68% | 12.96% | |
| Ulcer Indexi | 11.04% | 14.87% | |
| Max daily dropi | 8.84% | 5.82% | |
| Max wkly dropi | 12.84% | 17.03% | |
| 5Y | Growthi | -35.85% | -2.72% |
| CAGRi | -8.50% | -0.55% | |
| Volatilityi | 47.28% | 43.96% | |
| Sharpe ratioi | -0.05 | 0.10 | |
| Sortino ratioi | -0.07 | 0.15 | |
| Max drawdowni | 76.52% | 76.50% | |
| Current drawdowni | 36.38% | 18.07% | |
| Avg drawdowni | 58.56% | 41.27% | |
| Ulcer Indexi | 59.81% | 46.83% | |
| Max daily dropi | 9.72% | 11.07% | |
| Max wkly dropi | 24.54% | 31.57% | |
| 10Y | Growthi | +218.28% | +626.08% |
| CAGRi | +12.29% | +21.95% | |
| Volatilityi | 42.08% | 38.07% | |
| Sharpe ratioi | 0.38 | 0.60 | |
| Sortino ratioi | 0.55 | 0.85 | |
| Max drawdowni | 83.59% | 80.01% | |
| Current drawdowni | 55.54% | 18.17% | |
| Avg drawdowni | 40.08% | 26.98% | |
| Ulcer Indexi | 51.37% | 37.67% | |
| Max daily dropi | 13.76% | 15.11% | |
| Max wkly dropi | 27.43% | 31.57% |
| Category | ARKG | ARKW |
|---|---|---|
| Fund name | ARK Genomic Revolution ETF | ARK Next Generation Technology ETF |
| Type | ETF | ETF |
| Expense ratioi | 0.75% | 0.76% |
| Total assets (AUM)i | $2.21B | $1.68B |
| Dividend yieldi | 0.00% | 1.60% |
- Pure-play, high-conviction exposure to gene-editing and genomics innovation
- Active management can capitalize on fast-moving scientific breakthroughs
- Potential for outsized gains if genomic medicine breakthroughs accelerate
- High-conviction, actively managed exposure to disruptive internet trends
- Can capture outsized gains from breakthrough technology adoption
- Diversified across cloud, AI, and blockchain sub-themes
- Extremely volatile with a history of deep, multi-year drawdowns
- Concentrated in small, often unprofitable biotech companies
- Active management style has led to significant style-timing risk
- Extremely volatile with deep historical drawdowns
- Concentrated, high-conviction bets increase single-stock risk
- Active management style can badly lag during growth-stock corrections
Compare more than two at a time
This page is a fixed writeup on ARKG and ARKW. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside ARKG and ARKW, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.